Tag: Africa

CANBERRA, Australia and SAN DIEGO, June 23, 2021 (GLOBE NEWSWIRE) — Liquid Instruments, an innovator in precision software-defined instrumentation, today announced Moku:Pro, a high-performance platform for engineering and research labs.

Moku:Pro accelerates the transition from traditional fixed-function test and measurement hardware to a flexible field-programmable gate array (FPGA)-based approach by making high-quality instruments accessible in an integrated, software-upgradeable platform.

“Researchers in engineering and physics face constantly evolving requirements – with changes occurring on timescales much shorter than the lifespan of test equipment,” said Daniel Shaddock, CEO of Liquid Instruments. “Moku:Pro’s software-enabled-hardware architecture allows it to evolve as your applications evolve, something that is simply not possible with conventional test equipment.”

Moku:Pro hosts nine powerful instruments, including an oscilloscope, lock-in amplifier, PID controller, phasemeter, arbitrary waveform generator, data logger, spectrum analyzer, frequency response analyzer, and waveform generator to ensure researchers have the instrumentation they need to quickly characterize their set up and scale their experiments. The platform was designed to meet the needs of researchers in a variety of fields, from aerospace to semiconductor. Moku:Pro’s instrument suite is particularly suited to photonics applications, including spectroscopy, microscopy, metrology, gravitational wave detection, active laser stabilization, and quantum computing.

Bringing Instrumentation Into the Modern Era
Moku:Pro brings test and measurement into the modern age, allowing engineers and researchers to dynamically switch between instruments rather than needing multiple stand-alone devices.  Advanced ADC blending technology ensures that each instrument can function with optimal sensitivity from RF to acoustic frequencies without compromising performance for flexibility. Full connectivity via Wi-Fi, Ethernet, and USB-C ensures industry-standard, hassle-free configuration.

A key benefit of software-defined instrumentation is that it gets better over time. Moku:Pro can receive over-the-air updates to deliver improved specifications, new instruments, or entirely new capabilities. Users can expect to see these benefits as soon as September when Liquid Instruments plans to release a feature that will give Moku:Pro the ability to run multiple instruments in conjunction with one another and hot-swap instruments in and out. In this multi-instrument mode, instruments can be combined and connected to form sophisticated signal-processing pipelines. Also slated for September release is a new cloud-based tool that will allow users to directly program Moku:Pro’s FPGA. With this capability, users can implement unique signal processing algorithms and create their own custom instruments, which will further widen the gap with conventional hardware.

Moku:Pro Specifications

• 4 analog inputs and outputs
• Blended ADC input (10-bit+18-bit) for low noise, high bandwidth applications
• Sampling rate of 5 GSa/s (1 channel), 1.25 GSa/s (4 channels)
• 9 integrated instruments, including a DC-600 MHz lock-in amplifier
• 120 GB SSD for high-speed onboard storage
• API support for Python and MATLAB
• Starting at $12,000 for the base configuration, ranging up to $20,000 for the full suite.

A History of Success 
The Liquid Instruments technical leadership team brings deep expertise in complex measurements with experience from Australian National University, Max Planck Institute, Lockheed Martin, Caltech, and NASA’s Jet Propulsion Laboratory.  Moku:Pro expands the line of software-defined solutions from Moku:Lab, a twelve-instrument platform for research, and, more recently, Moku:Go, a complete and portable lab solution for undergraduate education.

For more information on Moku:Pro, visit: liquidinstruments.com

About Liquid Instruments
Liquid Instruments is a leader in precision software-defined instrumentation and is revolutionizing the way that students, engineers, and scientists learn, work, and discover. Their product line of hardware and software solutions leverages the computational power of modern FPGAs to create highly customizable instrumentation for controlling experiments and acquiring and analyzing data. The team’s IP in software-defined hardware enables Moku products to be dynamically reconfigurable in the field, serving a wide range of ever-changing experimental and process control situations. For more information, visit https://liquidinstruments.com.

The Project received funding from The Australian Government. Liquid Instruments gratefully acknowledges funding and support of the Australian Commonwealth Government through the CRC-P program administered by the Department of Industry Innovation and Science.

Media Contact
Codeword for Liquid Instruments
liquidinstruments@codewordagency.com
801-703-4092

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/37cb06a3-2242-4fe9-b6d2-0243a826051f

https://www.globenewswire.com/NewsRoom/AttachmentNg/8e84cd5f-7bf1-4276-9950-f57a12cfac19

Rotterdam, The Netherlands, June 21, 2021 (GLOBE NEWSWIRE) —

Summary:

• Centrient Pharmaceuticals has started production at its newly built statins API manufacturing unit in Toansa, India.
• With this expansion the company is doubling its production capacity of Atorvastatin and Rosuvastatin, meeting the increased demand for its high-quality uniquely produced statins.
• Centrient Pharmaceuticals’ statins are one of the most sustainably produced in the industry by eliminating harmful solvents, generating less waste, and a reduced carbon footprint of 32% as compared to traditional manufacturers.
• Using backward integrated manufacturing methods, and dedicated production facilities, Centrient Pharmaceuticals is able to offer its customers security of supply.

Centrient Pharmaceuticals (“Centrient”), the global leader in sustainable antibiotics, next-generation statins and anti-fungals, announced today to have started production at its new statins manufacturing unit. With the building of its second dedicated unit on the Toansa site in India now completed, the company will double its statins production capacity. This will enable Centrient to meet growing demand for its sustainably manufactured Atorvastatin and Rosuvastatin Active Pharmaceutical Ingredients (APIs).

Statins are currently the most prescribed drug class globally for the treatment of high cholesterol and cardiovascular diseases and are among the top-selling drugs worldwide. The markets for Atorvastatin and Rosuvastatin in particular, has shown steady growth in the past years, as a result of the continued global prevalence of high cholesterol issues, replacement of older generation statins, and genericization of the market.

Starting almost a decade ago, Centrient has grown today into one of the leading statin API suppliers worldwide, servicing large pharma companies around the globe.

Next to high-quality features like long shelf life and large batch sizes, the company offers security of supply to customers through its dedicated statins production facility and backward integration. Being backward integrated, Centrient is independent from external imports of starting materials. Its enzymatic route of synthesis and patented technology minimise the use of harmful solvents, generate less waste, and reduce the company’s carbon footprint by 32% as compared to traditional manufacturers.

The news of the facility expansion follows major milestones on statins that the company reached in the past years. In 2012, under the name of DSM Sinochem Pharmaceuticals, it was the first pharmaceutical manufacturer worldwide to offer generic Atorvastatin APIs under a Certificate of Suitability to the Monograph of the European Pharmacopoeia (CEP). Since 2014, it has produced the unique Atorvastatin APIs in its state-of-the-art facility in Toansa, India for third-party customers.

In addition, the company was one of the first three companies worldwide that started to offer generic Rosuvastatin APIs under CEP in 2016. Two years later, the first generic Rosuvastatin and Atorvastatin finished dosage forms were launched in Western Europe.

“With the doubling of our production capacity, we demonstrate our commitment to maintain our leadership position in line with our strategy and to continue supporting our customers’ business growth. Guided by our brand promise of Quality, Reliability, and Sustainability, Centrient’s Rosuvastatin and Atorvastatin offer superior performance in all three areas to the benefit of our customers and the environment.”, says Frans Vlaar, Chief Commercial Officer at Centrient.

Ground breaking of the new manufacturing unit started at the end of 2019 and commercial supplies from the new unit will start in mid-2021. With the new manufacturing line being operational and doubling the production capacity, Centrient will be even better positioned to secure supply, meeting the growing demand from customers and helping to improve the lives of patients who are in need of these medicine.

“We are extremely proud that we have been able to complete this project in a timely way given the challenges of executing such a complex project in the midst of the COVID pandemic,” says Jim McPherson, Chief Quality & Technical Operations Officer. “It reinforces our absolute commitment to meet the expectations of our customers as a partner of choice – delivering reliable and secure supply using leading sustainable technologies. The facility incorporates design features that allow further improvements in GMP and energy utilization, and enable greater automation for improved process control.”

———————————————————————————————————————————–

About Centrient Pharmaceuticals

Centrient Pharmaceuticals is the leading manufacturer of beta-lactam antibiotics, and a provider of next generation statins and antifungals. We produce and sell intermediates, active pharmaceutical ingredients and finished dosage forms.

We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 2200 employees work continuously to meet our customers’ needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance.

Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, Egypt, the United States and Mexico. Centrient Pharmaceuticals is wholly owned by Bain Capital Private Equity, a leading global private investment firm.

For more information please visit www.centrient.com or contact Centrient Pharmaceuticals Corporate Communications, Alice Beijersbergen, Director Branding & Communications. E-Mail: alice.beijersbergen@centrient.com.

Forward-looking statements
This press release may contain forward-looking statements with respect to Centrient Pharmaceuticals’ future financial performance and position. Such statements are based on current expectations, estimates and projections of Centrient and information currently available to the company. Centrient cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. Centrient has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is governing.

Alice Beijersbergen
Centrient Pharmaceuticals
alice.beijersbergen@centrient.com

Janet D’Addario

The cause was complications from gall bladder cancer, said her husband, Jim D’Addario.

Janet Marie D’Addario was born on December 10^th, 1948 in Nassau County. Her education circumnavigated Long Island: St. Brigid in Westbury; St. Dominic’s High School in Oyster Bay, and Nassau Community College in Garden City.

In 1966, the course of her life would forever change when the 18-year-old lead singer of a folk group met another young, budding musician who was instantly smitten by her tender voice and magnetic personality. Jim and Janet D’Addario would go on to marry, sing and perform on stage together, and start an extraordinary 50-year partnership that produced a family, a philanthropic legacy, and the most prestigious music accessories business in the world.

When D’Addario & Co. was first founded in 1973, Janet used her creative talents to design the company’s advertising as well as the packaging design for all of their products. As a fledgling organization, Janet’s vision and compassion had a tremendous influence on the development of the culture that guides the organization today.

She would go on to wear many hats, including head of Artist Relations and co-founder of the D’Addario Foundation, which continues to provide music education to young children in underserved communities. Janet served as the Managing Director of the Foundation for 20 years—helping to raise awareness for the cause by producing classical music concerts in cities around the world.

Ms. D’Addario was known by family and friends for her peerless compassion and generosity—fervently believing that actions mean far more than just words. She would go on to serve 11 years on the Board of Long Island Cares, the charity created by Harry Chapin to eradicate hunger on Long island. As a devout Catholic, she supported numerous Catholic charities across the globe, the Long Island Catholic Hospital system as well as her own, personal parish, St. Brigid.

The one charity that held a particularly special place in her heart was Providence House, a New York institution that provides transitional housing for homeless women and children.

“Providence House is, in so many ways, the very embodiment of my wife…when she saw pain, she wanted to ease it. When she saw hunger, she brought food. When she saw homelessness, she provided shelter. But most importantly when Janet saw someone with no hope, she worked hard to provide them with the tools to restore their will to overcome the challenges they were facing.,” said Jim D’Addario.

Ms. D’Addario served as a Board Member of Providence House for 21 years and as its President from 2004-2019. Over those years, she helped raise millions of dollars to ensure thousands of women and children would have a pathway to a brighter future. Her invaluable work led to Janet and Jim being named the first People of Hope in 2002 and the construction of the 43-unit D’Addario Residence in Bedford Stuyvesant, Brooklyn.

In addition to her philanthropic work, Janet was an avid foodie and prolific painter. Not surprisingly, her greatest joy was bringing friends and family together for a homemade meal and the occasional musical performance by she and Jim, as well as their many musical friends.

Janet D’Addario was the daughter of Robert James Carbone and Annabelle (Eannaccone) Carbone of Westbury, New York. She is survived by her loving husband of over 50 years, Jim D’Addario, and their three children: Julie (Pat); Amy (Marcus) and Robert (Gina). She is also survived by eight grandchildren, and her beloved dogs, Dave and Blue.

In lieu of any gifts or flowers, the family is asking anyone wishing to pay their respects to consider a modest donation to Providence House (https://www.providencehouse.org/support-our-work).

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/88f5885b-1766-4876-89ab-810766a28ed6

Natalie Morrison
natalie.morrison@daddario.com

 

TEMECULA, Calif., June 16, 2021 (GLOBE NEWSWIRE) — Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (“Group”), a subsidiary of Nikkiso Co., Ltd (Japan), is proud to announce they have signed an agreement for Asas Aljood to become the Authorized Service Provider for Nikkiso Cryogenic Services (NCS) in the Kingdom of Saudi Arabia.

With the growth of the Middle East market, this agreement allows the Group to extend their regional presence for the industrial gases, hydrogen, natural gas processing and petrochemical industries. Beginning July 1, 2021, Asas Aljood will utilize their local workshops to offer aftermarket service and support for both pumps and turbo expanders including packaging, repairs, spare parts and field service.

Based in Dammam, Asas Aljood will serve to strengthen our existing regional presence in addition to the Group’s Middle East operation in Sharjah (UAE).

“The newly formed partnership with Nikkiso and Asas Aljood gives us strong regional presence in Saudi Arabia and strengthens our ability to better serve the Middle East markets,” according to Jim Estes, President, Nikkiso Cryogenic Services. “I am looking forward to continuing to provide Nikkiso’s customers top quality service and support by eliminating costly downtime to their operations and processes.”

Asas Aljood is a leading provider of support and maintenance services in the oil & gas, petrochemical and energy industries, among others.

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture engineered cryogenic gas processing equipment and small-scale process plants for the liquefied natural gas (LNG), well services and industrial gas industries. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Cosmodyne and Cryoquip and a commonly-controlled group of approximately 20 operating entities.

For more information please visit www.nikkisoCEIG.com and www.nikkiso.com.

MEDIA CONTACT:

Anna Quigley
+1.951.383.3314
aquigley@cryoind.com